Infinimmune Appoints Dr. Neela Patel to Board of Directors
Dr. Patel is a seasoned life sciences executive and experienced board member who brings decades of pharmaceutical and biotechnology industry leadership experience and strong drug development expertise, including a track record of successful U.S. and global pharmaceutical licensing deals.
Biotech Showcase: Removing Barriers – Healthcare Access and Equity for All
Join Wyatt McDonnell as he appears as a panelist during this event.
Infinimmune, Grid Therapeutics Strike Antibody-Based Cancer Drug Discovery Partnership
RESI JPM 2024 Big Pharma Panel
Join us as Wyatt McDonnell moderates this RESI panel.
Infinimmune Announces Partnership with Grid Therapeutics to Conduct Deep Sequencing of B Cells for Oncology Drug Discovery
“Infinimmune, a biotechnology company pioneering new methods for antibody drug discovery and development, today announced a partnership with Grid Therapeutics (“Grid”), a clinical stage biotechnology company that focuses on human-derived antibodies, to collaborate in identifying new antibody drug candidates for non-small cell lung cancer.”
Bio’s Next Tool Builders
Infinimmune’s founding team are tool builders who design from first principles and have broad expertise across immunology, single cell technologies, protein engineering, computational biology, and genome assembly.Transforming human antibodies into drugs.
Infinimmune Raises $12 Million in Seed Funding
“Infinimmune combines a world-class team of technologists with a state-of-the-art platform for the discovery, characterization, and validation of truly human antibodies,” said Eddie Eltoukhy, Partner at Pear VC.
$12-Million Seed Funding to Design Drugs Using Human-Sourced Antibodies
Early-stage biotechnology company Infinimmune, which is developing novel techniques for antibody drug discovery and development, announced that it has closed a $12-million seed round led by Playground Global, with participation from Pear VC, Civilization Ventures, and Axial VC and support from Ron Alfa, Jacob Becraft, Paul Conley, and Joshua Meier.
Infinimmune’s secret for building better antibody drugs: You
San Francisco Business Times: An East Bay startup is looking to create antibody drugs at the source: humans. Infinimmune, with six people and a fresh $12 million seed round, is made up of veterans of 10x Genomics Inc., the Pleasanton-based company that pioneered single-cell sequencing technology. But the startup’s founders want to turn those types of tools into an engine for finding and developing drugs made from human antibodies.
Spotlight on Infinimmune
Infinimmune is a biotechnology company pioneering a novel approach to antibody drug discovery and development. Founded by a world-class, multidisciplinary team of scientists and technologists, Infinimmune is reinventing antibody discovery with an end-to-end platform to deliver antibody drugs derived directly from the human immune system.